Dyne Therapeutics
102 hedge funds and large institutions have $566M invested in Dyne Therapeutics in 2022 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 14 closing their positions.
5,070% more call options, than puts
Call options by funds: $517K | Put options by funds: $10K
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
76% more capital invested
Capital invested by funds: $321M → $566M (+$245M)
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
13% more funds holding
Funds holding: 90 → 102 (+12)
4.31% less ownership
Funds ownership: 90.39% → 86.08% (-4.3%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$26.3M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$3.97M |
| 3 |
Goldman Sachs
New York
|
+$3.8M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.53M |
| 5 |
O
OrbiMed
New York
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.3M |
| 2 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$8.48M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.02M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.58M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.62M |
DYN Hedge Fund Activity: Q3 2022 in Review
102 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2022, worth a combined $566M — up 76% from $321M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new DYN positions and 14 closed out — a net gain of 12 holders — while 32 added to existing stakes and 28 trimmed.
The largest buyer was Wasatch Advisors, opening a new position worth an estimated $26.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.3M sold.
- 102 institutional investors held Dyne Therapeutics (DYN) as of Q3 2022, up from 90 in Q2 2022.
- Funds reported $566M of Dyne Therapeutics stock for Q3 2022, up 76% quarter-over-quarter.
- 26 funds opened new Dyne Therapeutics positions in Q3 2022 and 14 closed out, a net change of +12 holders.
- The largest Dyne Therapeutics buyer in Q3 2022 was Wasatch Advisors, an estimated $26.3M added.
- The largest Dyne Therapeutics seller in Q3 2022 was RA Capital Management, an estimated $19.3M sold.
Based on aggregated 13F filings for Q3 2022.